Document Detail


Targeting eosinophils in allergy, inflammation and beyond.
MedLine Citation:
PMID:  23334207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic disorders such as asthma and allergy, as well as diseases that are not primarily associated with eosinophils, such as autoimmunity and malignancy. Eosinophil-targeted therapeutic agents that are aimed at blocking specific steps involved in eosinophil development, migration and activation have recently entered clinical testing and have produced encouraging results and insights into the role of eosinophils. In this Review, we describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight strategies for using personalized medicine to treat eosinophilic disorders.
Authors:
Patricia C Fulkerson; Marc E Rothenberg
Related Documents :
23272417 - Vasculitis: pathophysiology, diagnosis and treatment.
24415857 - Current issues in pediatric inflammatory bowel disease-associated arthropathies.
6772377 - The viral diseases of fish: a review through 1978. part 1: diseases of proven viral eti...
19891867 - Multicenter geosentinel analysis of rickettsial diseases in international travelers, 19...
12116607 - The controversy over estrogen replacement therapy: an update on clinical trials.
9386247 - Post-traumatic hydrops.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2013-01-21
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  12     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-01     Completed Date:  2013-04-22     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  117-29     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Eosinophils / drug effects*,  immunology,  pathology
Humans
Hypersensitivity / drug therapy*,  immunology,  pathology
Inflammation / drug therapy*,  immunology,  pathology
Molecular Targeted Therapy / methods
Grant Support
ID/Acronym/Agency:
K08 AI093673/AI/NIAID NIH HHS; K12HD028827/HD/NICHD NIH HHS; P01HL076383/HL/NHLBI NIH HHS; R01 AI083450/AI/NIAID NIH HHS; R01AI045898/AI/NIAID NIH HHS; R01AI057803/AI/NIAID NIH HHS; R01AI061097/AI/NIAID NIH HHS; R01AI083450/AI/NIAID NIH HHS; R01DK076893/DK/NIDDK NIH HHS; R37 AI045898/AI/NIAID NIH HHS; R37AI045898/AI/NIAID NIH HHS; U01AI088806/AI/NIAID NIH HHS; U19AI066738/AI/NIAID NIH HHS; U19AI070235/AI/NIAID NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mucosal maxillary cysts: long-term subjective outcomes after surgical treatment.
Next Document:  Clinical targeting of the TNF and TNFR superfamilies.